With JAX's new Cytokine Release Evaluation Study, have confidence about the safety of your therapeutic prior to entering clinical trials. With our novel humanized mouse platform for Cytokine Release Syndrome (CRS), you can test a candidate therapy for immunotoxicity alone (without the presence of a tumor) or for both immunotoxicity and drug efficacy in the same study (in the presence of a tumor) using a variety of donors. You’ll receive fast, reproducible, reliable, translationally-relevant results.
When testing the safety of your drug, you’ll receive data that is more predictable and reliable than any other method. Using JAX PBMC donors, you can have donors with varying responses, giving positive and negative controls, and allowing the ability to test variable dosing in response to the same immunomodulating therapies, such as bispecific, checkpoint inhibitors, and more.
This platform is ideal for evaluating relative cytokine levels from immunomodulating therapies and for assessing anti-inflammatory therapies.
Dr. Jim Keck gives a brief explanation of CRS. Taken from the June 24, 2020 livestream "A Dialogue on Immunotoxicity and COVID-19-related CRS."
Allow essential cookies
Required for basic site operations.
Allow analytics cookies
Used to analyze web traffic to improve the user experience.
Allow marketing cookies
Used to deliver personalized information and tailor communications.